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Table 1. Wide-spread loss of expression of the proteins tested by IHC.

Loss of expression was defined as 0-5% of staining within tumor nuclei in
any 1 mm2	
  focus. Discrepancies in scores were resolved by pathologic
re-review by the two pathologists, and consensus was reached. Fisher’s
exact test was used for statistical analysis, and a p value <0.05 was
considered statistically significant.
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BRG1

15% (24/160)

BRM

38% (61/160)

PBRM1

31% (49/160)

ARID1A

51% (81/160)

SETD2

14% (23/160)

Strikingly, novel co-loss patterns were identified among these proteins.

v ARID1A loss almost always accompanied PBRM1 loss.
v BRM loss almost always accompanied BRG1 loss, PBRM1 loss or
Arid1A loss
v SETD2 loss almost always occurred with the loss of one or more of the
other four proteins.
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The 2-sided p values for the above associations (Fisher’s exact tests)
were all <0.0001, and the strong positive associations were true when
tumor foci or tumors were compared.

CONCLUSIONS
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*Red circles highlighted the subunits tested in this
study. SETD2 is not shown in this figure.
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The importance of the SWI/SNF complex and related pathways are
highlighted by the wide-spread loss of protein expression in its
components. The loss of protein expression of BRG1 and especially BRM
in ccRCC are novel findings. As mutational analysis may be expensive and
rarely covers hundreds of samples, routine IHC method provides a
relatively quick and reliable method to assess tumor heterogeneity in large
number of cases. It is also striking to find the co-losses of SWI/SNF
components in ccRCC. As genetic interactions play powerful roles in
tumorigenesis, these findings will provide insights and guidance to basic
research and therapeutics.
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Figure 2. Examples of immunostains for components of chromatin
remodeling complex pathway in ccRCC.
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Wide-spread loss of expression was identified in the proteins
analyzed (see Table 1).
Very high percentage of tumors displays heterogeneity in loss of
expression, since frequently < 4 foci from the same tumor had
loss of a certain protein.
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